About Dimebon
Dimebon is an orally available, small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer’s disease and Huntington’s disease, making it a potential treatment for these and other neurodegenerative diseases.
Dimebon first pivotal trial data summary
In a recent pivotal clinical trial of Dimebon in patients with mild to moderate Alzheimer’s disease, Dimebon demonstrated statistically significant benefit versus placebo on the most frequently studied aspects of Alzheimer’s disease:
- Cognition and memory
- Overall clinical function
- Activities of daily living
- Behavioral problems
A novel approach to Alzheimer’s disease
Based on the clinical and preclinical data generated to date, it is believed that the mechanism of action of Dimebon is unlike that of any approved Alzheimer’s disease medication. Dimebon appears to stabilize and improve mitochondrial function in a way that prevents neuron death and dysfunction.
Learn more about Dimebon at Medivation.com.
